CTRI/2022/10/046449尚未招募未知
A prospective randomized study of safety and efficacy of bilastine updosing (40mg) vs combination of bilastine 20mg with levocetrizine 5mg in the treatment of chronic spontaneous urticaria
SRM Medical college hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •patients previously treated with bilastine 20mg for 2 weeks but developing new lesions
排除标准
- •Hereditary angioedema
- •Food or drug allergy
- •Collagen vascular diseases
- •Atopic dermatitis
- •Systemic autoimmune disorders
- •Hodgkinââ?¬•s disease
- •Pregnant and lactating women
- •Patients on systemic or topical corticosteroids within 4 weeks
研究者
相似试验
进行中(未招募)
不适用
Randomized study on the effectiveness, safety and acceptability 'of clobetasol propionate foam-cooled (OLUX) in comparison with cream aceponato methylprednisolone in the treatment of allergic contact dermatitis. - OLUX 01/08Patients suffering from mild to moderate DAC with interest of body surface area not exceeding 20%MedDRA version: 9.1Level: LLTClassification code 10056265Term: Allergic contact dermatitisEUCTR2008-004331-38-ITMIPHARM
尚未招募
3 期
A Study of AAV5-hRKp.RPGR for the Treatment ofJapanese Participants with X-linked Retinitis PigmentosaX-Linked Retinitis PigmentosaJPRN-jRCT2031230141umaguchi Hirotaka4
进行中(未招募)
不适用
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral DensityPostmenopausal Osteoporosis/osteopeniaEUCTR2006-000849-19-EEAmgen Inc500
进行中(未招募)
不适用
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral DensityEUCTR2006-000849-19-PTAmgen Inc500
进行中(未招募)
不适用
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy from Alendronate to Denosumab AMG 162 in Postmenopausal Women with Low Bone Mineral Density - STANDEUCTR2006-000849-19-ITAMGEN S.P.A.500
